Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Short-term Investments (2017 - 2025)

Anaptysbio's Short-term Investments history spans 9 years, with the latest figure at $73.4 million for Q4 2025.

  • For Q4 2025, Short-term Investments fell 72.0% year-over-year to $73.4 million; the TTM value through Dec 2025 reached $73.4 million, down 72.0%, while the annual FY2025 figure was $73.4 million, 72.0% down from the prior year.
  • Short-term Investments reached $73.4 million in Q4 2025 per ANAB's latest filing, down from $139.1 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $394.3 million in Q2 2023 to a low of $60000.0 in Q2 2021.
  • Average Short-term Investments over 5 years is $242.1 million, with a median of $270.6 million recorded in 2024.
  • Peak YoY movement for Short-term Investments: plummeted 99.96% in 2021, then soared 640598.33% in 2022.
  • A 5-year view of Short-term Investments shows it stood at $52.4 million in 2021, then surged by 606.41% to $369.9 million in 2022, then decreased by 4.05% to $354.9 million in 2023, then fell by 26.1% to $262.3 million in 2024, then plummeted by 72.0% to $73.4 million in 2025.
  • Per Business Quant, the three most recent readings for ANAB's Short-term Investments are $73.4 million (Q4 2025), $139.1 million (Q3 2025), and $221.4 million (Q2 2025).